Benitec Biopharma Inc (BNTC) stock face negativity in both sessions on Tuesday, April 27, 2021. In the normal trading session, BNTC lost 1.97% and further, it lost 20.44% in the after-hours trading to close at $4.36 per share.
BNTC shares have lost 49.02% over the last 12 months, and they have moved up by 23.42% in the past week. Over the past three months, the stock has gained 17.34%, while over the past six months, it has surged 88.97%.
Even if youâ€™re not actively in crypto, you deserve to know whatâ€™s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public â€ścrypto stocksâ€ť are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full storyâ€¦ along with our long list of backdoor Bitcoin strategies. Itâ€™s free.
Letâ€™s see why did BNTC did not perform well on Tuesday
Recent common stock offer
On April 27, 2021, Benitec Biopharma Inc. said that 1,764,705 shares of common stock of the company have been bought by H.C. Wainwright & Coat for $4.25 per share.
BNTC will get gross proceeds of approximatelyÂ $7.5 million and it will be used for the continued advancement of development activities for its product pipeline, general corporate purposes, and strategic growth opportunities.
Successful results of the BB-301 pilot dosing study
On February 24, 2021, Benitec Biopharma reported successful results of the interim analysis of the BB-301 Pilot Dosing Study.
BB-301 is a first-in-class genetic medicine used for the treatment of OPMD. OPMD is a chronic, life-threatening genetic disorder affecting approximately 15,000 patients inÂ the United States,Â Canada,Â Western Europe, and Israel.
Benitec demonstrated a 248-fold improvement and a 111-fold improvement in BB-301 transduction of the two key pharyngeal muscles.
The interim analysis showed highly consistent, dose-dependent levels of BB-301 tissue transduction, with BB-301 copy numbers ranging from 1.7 copies per cell up to 8.6 copies per cell achieved after a single administration of increasing doses of BB-301.
On September 23, 2020, Benitec Biopharma reported itsÂ financial results for its fiscal year endedÂ June 30, 2020. The company hasnâ€™t announced any further results yet.
FY 2020 financial highlights
- FY 2020 revenue was one hundred two thousand dollars compared to $12.2 million for the year ended June 30, 2019.
- It spent $8.4 million in total expenses in FY 2020compared to $9.6 million for FY 2019.
- $3 million were spent in research and development expenses in FY 2020 compared to $4.6 million in 2019.
- General and administrative expenses were $5.6 million in FY 2020 compared to $4.6 million in FY 2019.
- FY 2020 operating net loss was 8.28 million or $8.10Â per basic and diluted shareÂ compared to income ofÂ $2.58 millionÂ orÂ $3.05Â per basic and diluted share for fiscal 2019.
- BNTC had $9.8 million in cash and cash equivalents, on June 30, 2020.
The recent common stock offering could be the reason behind its poor performance on Tuesday. In the past 12 months, BNTC performance is great and it did not lose any significant value so we can expect it to bounce back in the coming days.